The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Launched by THE PEOPLE'S HOSPITAL OF GAOZHOU · Apr 9, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how well a medication called dapagliflozin works to improve heart failure in patients who are on dialysis. Heart failure can be a serious condition, and people on dialysis often experience more heart-related issues. While previous studies have shown that dapagliflozin may help protect the heart, most of that research has focused on patients who are not on dialysis. This trial aims to fill that gap by looking specifically at dialysis patients, particularly those whose kidney function is severely reduced.

To be eligible for the study, participants need to be between 20 and 70 years old, have been on dialysis for more than three months, and have a diagnosis of chronic heart failure. There are a few conditions that would exclude someone from participating, such as severe liver issues or being pregnant. If you join the trial, you will be closely monitored to see how well the medication works and to ensure your safety. This study is important because it could lead to better treatments for heart failure in dialysis patients, helping to improve their overall health and quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.Age between 20 and 70 years old; 2.Maintenance dialysis for longer than 3 months; 3.Diagnosis with chronic heart failure, Left ventricular ejection fraction (LVEF)≤40% or NT-proBNP\>12000pg/ml; 4.The patient signs an informed consent form.
• Exclusion Criteria:
• • 1.Patients with liver function impairment; 2.Patients with severe hypoglycemia/hypotension/ketoacidosis; 3.Patients with active pyelonephritis or symptomatic urinary tract infection; 4.Dapagliflozin allergies or severe adverse reactions; 5.Patients suffering from other severe diseases; 6.Patients participating in other clinical trials; 7.Pregnant or lactating women; 8.Failure to sign a written informed consent form; 9.Unable or unwilling to comply with the experimental protocol approved by the researcher